DocMorris AG reported a first-quarter revenue increase of 10.7% in local currency, bringing top-line sales to CHF318.1m. The performance reflected particular strength in its prescription drug business in Germany, where Rx sales reached CHF68.1m - a 26.4% rise year-over-year and a 6% increase quarter-over-quarter.
Company management said that prescription growth accelerated further in March following the introduction of bonus incentives on co-payments. That programme rollout was cited as a driver of the stronger Rx trend in the month.
On the user front, DocMorris recorded 12.6m active users at the end of March, an increase of 3.3% versus the prior quarter. The company noted that this compares with 12.2m users in 2025, which were composed of 11.0m users for the online pharmacy and 1.2m users at TeleClinic.
Non-prescription revenue also expanded, with reported-currency growth of 3.3% year-over-year and local-currency growth of 6.5%. Within that segment, over-the-counter products rose 4.4%, while digital services - a category that includes TeleClinic, retail media and marketplace activities - surged 63.1%.
Profitability metrics showed improvement. Adjusted EBITDA narrowed by almost CHF10m year-over-year to negative CHF6.3m in the first quarter.
Looking ahead, DocMorris reiterated its full-year 2026 outlook. The company is guiding to external revenue growth in a range from mid-single-digit to low-teens and expects adjusted EBITDA between negative CHF10m and negative CHF25m for 2026. Management also set operational targets to reach EBITDA break-even by the fourth quarter and to achieve free cash flow break-even in 2027.
Contextual note - The figures supplied above are taken from the company's reported quarterly update. Where the company highlighted programme effects and segment contributions, those points were presented as management's explanations of recent trends.
What this means for markets and sectors
- Health care and e-commerce sectors are directly affected by DocMorris' top-line and user-growth trends, given the company's position as an online pharmacy and digital health services provider.
- Digital services expansion, including TeleClinic and retail media, points to increasing monetization outside pure prescription fulfilment.